We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Weight Gain: A Possible Side Effect of All Antiretrovirals.
- Authors
Taramasso, Lucia; Ricci, Elena; Menzaghi, Barbara; Orofino, Giancarlo; Passerini, Simone; Madeddu, Giordano; Martinelli, Canio Vito; Socio, Giuseppe Vittorio De; Squillace, Nicola; Rusconi, Stefano
- Abstract
Weight gain and body mass index (BMI) increase are central issues in patients living with HIV who need to minimize the risk of metabolic disease. Information collected through the SCOLTA cohort revealed significant 1-year BMI increase in patients treated with dolutegravir (P =.004), raltegravir (P =.0004), elvitegravir (P =.004), darunavir (P =.0006), and rilpivirine (P =.029). BMI gain correlated with low baseline BMI (P =.002) and older age (P =.0007) in Centers for Disease Control and Prevention stages A/B, with lower BMI (P =.005) and CD4+ T-cell count (P =.007) at enrollment in stage C.
- Subjects
METABOLIC disorders; ANTI-infective agents; CENTERS for Disease Control &; Prevention (U.S.); HIV infections; HIV-positive persons; WEIGHT gain; ANTIRETROVIRAL agents; BODY mass index; DARUNAVIR; RALTEGRAVIR; HIV integrase inhibitors; CD4 lymphocyte count; LYMPHOCYTE count; RILPIVIRINE; DISEASE risk factors
- Publication
Open Forum Infectious Diseases, 2017, Vol 4, Issue 4, pN.PAG
- ISSN
2328-8957
- Publication type
Article
- DOI
10.1093/ofid/ofx239